Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage biotechnology company renowned for its innovative therapies targeting oncology and central nervous system disorders, is set to present at the upcoming Leerink Partners Global Healthcare Conference in Miami, Florida, from March 8-11, 2026. The company's CEO, Sergio Traversa, and CFO, Maged Shenouda, will engage in a fireside chat on March 10, 2026, at 8:40 AM ET, showcasing the company's advancements and strategic direction.

Relmada's primary focus centers on developing transformative therapies that cater to significant unmet medical needs in oncology and mental health. The company is advancing its lead candidates, NDV-01 and sepranolone, through mid-stage clinical development, demonstrating its commitment to addressing critical health challenges. NDV-01 is being evaluated for its potential in treating various cancers, while sepranolone aims to offer new hope for patients with central nervous system disorders.

In addition to the fireside chat, Relmada's management is open to one-on-one meetings with investors during the conference, encouraging attendees to reach out to their Leerink Partners representative to schedule discussions. For those unable to attend in person, the event will be accessible via a webcast on Relmada's investor relations website, with an archived replay available for 90 days post-conference.

As Relmada Therapeutics continues to develop and refine its clinical offerings, participation in significant industry conferences like the Leerink Partners Global Healthcare Conference underscores its ongoing efforts to innovate and enhance patient outcomes in challenging therapeutic areas. More information about the company and its pipeline of products can be found on their official website at www.relmada.com.

Relmada Therapeutics, Inc. (Nasdaq: RLMD) is poised for significant visibility at the upcoming Leerink Partners Global Healthcare Conference, which may serve as a pivotal moment for the company, especially with its focus on oncology and central nervous system disorders. The participation of CEO Sergio Traversa and CFO Maged Shenouda in a fireside chat on March 10, 2026, positions the company to engage with a broad spectrum of investors and stakeholders, highlighting the ongoing development of its lead drug candidates, NDV-01 and sepranolone.

As a clinical-stage biotechnology firm, Relmada operates in a highly competitive and rapidly evolving market. Investors should closely monitor the outcomes from this conference, particularly how management articulates the therapeutic potential of their key candidates and addresses market expectations regarding their clinical trials. Given that both NDV-01 and sepranolone are in mid-stage development, any insights into trial progress, regulatory milestones, or partnership opportunities could significantly influence investor sentiment and stock performance.

From a market advice standpoint, potential investors might view this conference as an opportunity to gauge the company's roadmap and its preparedness to capitalize on emerging market trends in biopharmaceuticals. Additionally, the one-on-one meeting opportunities could yield further insights into the strategic vision of Relmada, mitigating some inherent risks associated with investing in clinical-stage entities.

As always, it's essential to analyze market conditions, regulatory environments, and the competitive landscape when considering any financial commitments. Monitoring the stock price leading up to and following the conference will be crucial, as technology and innovation often drive volatility in the biotech sector. While Relmada holds promising prospects, a prudent approach would be to weigh these opportunities against potential market fluctuations and the inherent risks in biopharmaceutical investment.